Concepedia

Daniel J. Trepanier

DJ

Statistics

Publications

11

Citations

300

H-Index

11

Active since

1996

Affiliations

Edison Pharmaceuticals (United States)(Current)

Scripps Research Institute

University of Windsor

University of Alberta

NAEJA-RGM Pharmaceuticals (Canada)

Daniel J. Trepanier is an author at Edison Pharmaceuticals (United States) specializing in pharmacology, pharmacy, and drug disposition.

ORCID

Publications per year

1996–2022

11

Publications

11

Psychological support for the Canadian Olympic Boxing Team in meta-transitions through the National Team Program

Robert J. Schinke, Natalia Stambulova, Daniel J. Trepanier et al. · International Journal of Sport and Exercise Psychology · 2014 · 52 citations

, , +10

A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models

Joseph Kuo, Michael Bobardt, Udayan Chatterji et al. · Journal of Pharmacology and Experimental Therapeutics · 2019 · 52 citations · Full text

, , +9

The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice

Philippe Gallay, Daren Ure, Michael Bobardt et al. · PLoS ONE · 2019 · 41 citations · Full text

, , +16

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action

Philippe Gallay, Michael Bobardt, Udayan Chatterji et al. · PLoS ONE · 2015 · 37 citations · Full text

, , +17

Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH

Stephen A. Harrison, Patrick Mayo, Todd M. Hobbs et al. · Hepatology Communications · 2022 · 28 citations · Full text

, , +14

1–5 of 11